Cochlear buys Philips Hearing Implants:

Australian company Cochlear has bought the technology of Philips Hearing Implants, which also develops cochlear implants. Philips' design and development facility in Antwerp, Belgium, has been renamed Cochlear Technology Centre Europe (CTC Europe). Some 30 employees will remain at the site, including Jan Janssen who will be general manager. The deal provides Cochlear with complementary cochlear implant technology and expertise, enabling it to get products to market faster and more effectively, the company, of Sydney, New South Wales, says.

Australian company Cochlear has bought the technology of Philips Hearing Implants, which also develops cochlear implants. Philips' design and development facility in Antwerp, Belgium, has been renamed Cochlear Technology Centre Europe (CTC Europe). Some 30 employees will remain at the site, including Jan Janssen who will be general manager. The deal provides Cochlear with complementary cochlear implant technology and expertise, enabling it to get products to market faster and more effectively, the company, of Sydney, New South Wales, says.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight